A new chapter of clinical trial excellence at Tennessee Oncology

Dr. Flinn previously served as the Director of Blood Cancer at Sarah Cannon Research Institute. His own research focuses on the development of new therapies for patients with lymphoma and chronic lymphocytic leukemia.

Jesús G. Berdeja received his undergraduate degree from Stanford University and medical degree from Harvard University. He completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco and fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore. An active researcher, Dr. Berdeja has been the principal investigator of many funded clinical trials in the field of multiple myeloma and cellular therapy. He has published extensively in the peer-reviewed literature and is a frequent invited lecturer.

Dr. Iams earned his medical degree from the University of Michigan, completed Internal Medicine Residency and a Chief Residency at Vanderbilt University, and completed his fellowship in medical oncology at Northwestern University. Prior to joining Tennessee Oncology, he was on faculty at Vanderbilt University Medical Center for six years, including three years as the Director of Thoracic Clinical Trials.

Dr. Nunnery earned her medical degree from the University of Tennessee Health Science Center and completed her Internal Medicine Residency at the University of California, San Francisco. She completed her fellowship in hematology/oncology at Vanderbilt University Medical Center and also completed her Master of Science in Clinical Investigation from Vanderbilt University. She was previously a breast oncologist at the Vanderbilt Breast Center and on faculty as an Assistant Professor of Medicine at Vanderbilt University Medical Center. Her goal at Tennessee Oncology is to bring the latest clinical trials with cutting-edge therapies to patients with breast cancer across the communities of middle and east Tennessee.

Dr. Russell earned his MD from the University of Texas at San Antonio, his PhD in Biomedical Sciences from Univ of Texas/MD Anderson, and his MBA from Temple University. He completed internal medicine training at UCSF and his fellowship in medical oncology at Stanford University. Dr. Russell was an assistant professor at Moffitt Cancer Center (Tampa, FL) specializing in head and neck cancers and then served as a Senior Medical Director of Early Clinical Development for Oncology at Janssen Pharmaceuticals. He then moved to the Huntsman Cancer Institute (Salt Lake City, UT) as an associate professor working with head and neck and cutaneous oncology patients. Throughout his academic career, he has been heavily involved in running and managing early and late phase clinical trials and his time in the pharmaceutical industry has given him a unique perspective on clinical trial development.